Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

Janku, Filip

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. [electronic resource] - Targeted oncology Sep 2013 - 183-188 p. digital

Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural

1776-260X

10.1007/s11523-013-0266-9 doi


Adult
Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Bevacizumab
Biomarkers, Tumor--genetics
Colorectal Neoplasms--drug therapy
GTP Phosphohydrolases--genetics
Humans
Male
Membrane Proteins--genetics
Middle Aged
Mutation
Treatment Outcome